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Abstract
While peptides are promising as probes and therapeutics, targeting intracellular proteins will 
require greater understanding of highly structured, cell-internalized scaffolds. We recently 
reported BC1, an 11-residue bicyclic peptide that inhibits the Src homology 2 (SH2) domain of 
growth factor receptor-bound protein 2 (Grb2). In this work, we describe the unique structural and 
cell uptake properties of BC1 and similar cyclic and bicyclic scaffolds. These constrained 
scaffolds are taken up by mammalian cells despite their net neutral or negative charges, while 
unconstrained analogs are not. The mechanism of uptake is shown to be energy-dependent and 
endocytic, but distinct from that of Tat. The solution structure of BC1 was investigated by NMR 
and MD simulations, which revealed discrete water-binding sites on BC1 that reduce exposure of 
backbone amides to bulk water. This represents an original and potentially general strategy for 
promoting cell uptake.
1. Introduction
Constrained peptides are an important class of biologically-inspired molecules with utility 
for inhibiting protein-protein interactions. A growing body of work has shown that precisely 
designed covalent constraints can improve peptide affinity, selectivity, metabolic stability, 
and in some cases, cell penetration.1 Cell internalization via endocytosis is frequently 
correlated to amphipathic character and positive charge, both of which promote association 
with the plasma membrane and induce various endocytic pathways.2,3 By contrast, there are 
strikingly few reports of conformationally constrained peptides with neutral or net negative 
charge that are taken up by mammalian cells.4-6 While the mechanisms of internalization for 
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polycationic sequences, including the HIV-derived Tat peptide, have been richly 
explored,3,7-9 comparatively little is known about the precise mechanisms by which non-
cationic, constrained peptides enter the cell.5,10,11 Herein, we report a series of neutral and 
negatively charged constrained peptides that are internalized by mammalian cells. We also 
report details of uptake mechanism and identify unique structural features that may promote 
cellular uptake.
The head-to-tail cyclic peptide HT1 and bicyclic peptide BC1 (Figure 1) were designed as 
inhibitors of the SH2 domain of Grb2.12 They were derived from disulfide- and thioether-
bridged macrocycles originally described by Roller and co-workers.13,14 BC1, which has an 
IC50 of 350 nM for Grb2 inhibition in biochemical assays, did not show anti-proliferative 
activity up to 30 μM (Supplementary Figure S1). This was not surprising, since small 
molecules that target Grb2-SH2 produced by Burke and colleagues inhibited the protein 
with potencies in the 1-20 nM range, but only affected cells in the 0.8-25 μM range.15,16 
These inhibitors of the SH2 domain have shown low-nanomolar affinity in vitro and yet 
were unable to disrupt the Grb2-pErbB2 interaction in live cells.15 This lack of cellular 
activity can be attributed to the high degree of negative charge characteristic of these 
phosphotyrosine isosteres and mimetics. Because our peptides did not demonstrate Grb2-
dependent effects on cultured cells, we were interested in whether the primary barrier was 
uptake of BC1 by mammalian cells or subsequent endosomal release. If BC1 was taken up 
by mammalian cells, even to a small extent, it would be surprising since most cell-
internalized peptides are highly cationic. Among peptides with less overall charge, such as 
amphipathic helices, a single negative charge is typically enough to completely prevent 
internalization.5,17-19 Thus, we designed a series of experiments to explicitly test the uptake 
of BC1 and analogs in cultured cells, in order to begin to elucidate how structured peptides 
could be designed to maximize cell uptake.
2. Results and Discussion
2.1. Cell uptake of dye-labeled cyclic and bicyclic peptides
Our first variants were designed to explore the role of the negative charge. Specifically, we 
prepared variants of HT1 and BC1 with BODIPY-FL conjugated to Glu1 to eliminate the 
negative charge (HT1-Neut and BC1-Neut), or with the dye conjugated to a Cys residue 
substituted for Met8 to maintain a net charge of-1 (BC1-Neg; see Figure 1 and 
Supplementary Figure S2). To explore the role of conformational constraint, we also 
prepared dye-labeled linear analogs, as well as a dye-labeled bicyclic scaffold with a 
different lactam cross-link (BC3-Neut, Supplementary Figure S2). BODIPY-FL-labeled Tat 
peptide (Tat-Bdy) was used as a positive control. We used confocal fluorescence 
microscopy to investigate the cellular uptake of these dye-labeled peptides using MDA-
MB-453 cells, a metastatic human epithelial cancer line. Confocal microscopy revealed that 
both BC1-Neg and BC1-Neut were internalized by MDA-MB-453 cells (Figure 2). Uptake 
was quantified using two independent measurements: ImageJ analysis of confocal 
microscopy images, and direct fluorometry of cell lysates following incubation and washing 
(Figure 3). Both techniques showed similar trends. The neutral BC1-Neut was internalized 
as effectively as Tat-Bdy, and, surprisingly, the anionic BC1-Neg was internalized almost 
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as effectively. Interestingly, BC3-Neut was internalized to a similar extent, implying that 
multiple bicyclic structures can be efficiently taken up by cells. The less rigid, monocyclic 
peptide HT1-Neut was taken up by cells to a similar extent as BC1-Neut, but linear 
peptides labeled at Glu1 (Lin-Neut) or at the N-terminus (Lin-Neg) were not effectively. In 
the case of these linear peptides, the discrepancy between the fluorescence exhibited by cell 
lysates and the quantification of confocal microscopy images suggests that some 
fluorescence was associated with cell lysates at high concentrations (5 μM peptide). In fact, 
visualization by confocal microscopy shows dim fluorescence localized to the exterior of the 
cell (experiments performed with 10 μM peptide).. However, this association diminishes 
dramatically at lower peptide concentrations. As shown in Figure 3b and Supplementary 
Figure S8, cell lysate fluorescence decreases very rapidly for these linear peptides at lower 
concentrations compared to lysates from cells incubated with bicyclic and cyclic scaffolds. 
Thus, for these scaffolds we observed a general correlation between structural rigidity and 
cell uptake for peptide concentrations below 10 μM. Similar results were observed for 
fluorescein-labeled peptides as well as for peptides with the dye attached at a third location 
(Supplementary Figure S4). We concluded that the observed uptake is an intrinsic property 
of these constrained scaffolds.
Some previous work has correlated degree of structure to cell penetration for other classes of 
constrained peptides.2,5,11 However, the precise mechanisms by which constrained peptides 
are taken up by the cell are still poorly understood. We sought to begin to characterize the 
mechanism of uptake for our cyclic and bicyclic scaffolds. The patterns of fluorescence 
associated with BC1-Neut and BC1-Neg contain a few bright punctate signals as well as 
more diffuse fluorescence that permeates the cytoplasm, with less fluorescence in the 
nucleus. HT1-Neut and BC3-Neut have more of their fluorescence distributed throughout 
the cytoplasm, with fewer visible puncta. These results are consistent with endocytic entry 
for these peptides, with some extent of endosomal escape. At 4° C, overall fluorescence 
intensity was dramatically reduced for all internalized cyclic and bicyclic scaffolds, but less 
reduced for Tat-Bdy, as expected due to the multiple modes by which Tat is internalized.3 
The role of clathrin-mediated endocytosis in facilitating cellular uptake was studied using 
the small-molecule dynamin inhibitor dynasore.20 Pre-treatment with dynasore resulted in 
increased formation of punctate fluorescence for Tat-Bdy, but resulted in increased cell-
surface localization for cyclic and bicyclic scaffolds (Figure 2, quantified in Supplementary 
Figures S5-S7). Taken together, these data implicate an energy-dependent, endocytic 
pathway for uptake of these constrained peptides that differs substantially from the uptake 
mechanism of Tat. Future work will apply emerging label-free methods, pathway-specific 
assays, and assays for quantitating endosomal escape to further refine our understanding of 
these peptides’ surprising cellular internalization.8,19,21
2.2. NMR structure and molecular dynamics of bicyclic peptide BC1 in aqueous solution
While the uptake of BC1 and related scaffolds is clearly dependent on constrained structure, 
prior work has demonstrated that rigidification does not automatically confer increased 
uptake.2,17,22 We hypothesized that specific structural features of BC1 promote its 
association with the plasma membrane, leading to uptake via endocytosis. To further explore 
this hypothesis, we determined the NMR structure of BC1 in aqueous solution. TOCSY, 
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NOESY, ROESY and 1H-13C HSQC NMR spectra were obtained for 0.76 mM BC1 in 9:1 
H2O:d6-DMSO. The recorded spectra were well-resolved and allowed complete resonance 
assignments (Supplementary Table S1). The Hα and amide proton chemical shifts of most 
residues differed significantly from typical values for random-coil structures, indicating the 
peptide adopts a well-defined structure (Supplementary Figure S9). 90 NOE-derived 
distance restraints were compiled (Supplementary Table S2), and these were used in multi-
stage simulated annealing calculations to produce a structural ensemble of thirty lowest-
energy structures (Figure 4A-B).
Figure 4B shows the solution structure of the BC1 backbone (RMSD 0.33 Å). The backbone 
of Ala11 through Tyr3 forms an unusual turn structure that points amide protons inward and 
carbonyl oxygens out towards solvent. This effectively shields the hydrogen bond donors 
from aqueous solvent. To explore how BC1 might interact with water, we performed all-
atom molecular dynamics simulations on a tethered model of the BC1 solution structure. 
During a 100 ns MD simulation in TIP4P explicit water using the OPLS/AA forcefield,23,24 
we observed three distinct water molecules that bind three separate pockets formed by 
backbone amides and carbonyls (Figure 4E, Supplementary Video Files). The most tightly 
bound water molecule in the simulation binds in a pocket defined by the inward-facing 
amide protons of Ala11, Glu1, Leu2, and Tyr3, providing a unique explanation for the 
conformation of this loop. Over the course of the 100 ns simulation, this pocket exhibited 
99% occupancy, with an average water molecule residence time of 1.4 ns and a calculated 
binding δδG of−2.74 kcal/mol. Discrete, bound waters are typical for protein surfaces,25-27 
but this behavior is unusual for small, constrained peptides. To find experimental evidence 
of water-binding sites, we further analyzed the NOESY and ROESY data. Specifically, we 
looked for cross-peaks between BC1 protons and the water line at 4.78 ppm, which occur 
when discrete water molecules persist for 100-300 ps or longer.28,29 Direct magnetization 
transfer to water was observed from several protons within BC1, including protons within 
Ala11, Glu1, Leu2, Tyr3, Pro4, Met8, and Lys9 (Supplementary Figure S11). These protons 
map closely to predicted water-binding sites suggested by MD simulations (Figure 4F), 
providing experimental evidence that the unusual backbone of BC1 binds discrete waters. 
This appears to reduce the overall number of solvent-exposed H-bond donors, because 
several amide protons are shielded from bulk solvent upon the binding of a single water 
molecule. Future work will explore whether this property is directly or indirectly responsible 
for cell uptake, and whether this property can be generalized for the design of constrained 
peptides and small molecule macrocycles.
2.3. Observation and proposed binding mode of a conformation-dependent 
phosphotyrosine mimic
Finally, prior work established that BC1 competes for the phosphotyrosine (pTyr) binding 
site on Grb2-SH2, and that BC1 is recognized by anti-phosphotyrosine antibodies.12 Still, 
the precise nature of the phosphotyrosine-like epitope was not established. The solution 
structure of BC1 allowed direct observation of the pTyr mimic. Many of the strongest NOEs 
were between side-chain protons of Glu1 and Tyr3, providing direct evidence that these side 
chains are in close contact. In the refined ensemble of structures, the side chains of Glu1 and 
Tyr3 form a discontinuous epitope that resembles pTyr (Figure 4C). To further validate that 
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these side chains form a pTyr-mimicking epitope, we tested BC1 variants with the 
conservative changes Glu1 to Asp, or Tyr3 to Phe (Supplementary Figure S12). These 
variants had no binding activity in a fluorescence polarization competitive binding assay 
(Supplementary Figure S13). Thus, we conclude that Glu1 and Tyr3 form a discontinuous, 
pTyr-mimicking epitope. To provide a more complete model for Grb2 binding, a 
representative BC1 structure was docked into the pTyr-binding site of Grb2-SH2 (Figure 
4D). This model demonstrated that BC1 is pre-organized in a manner consistent with direct 
binding to the pTyr-binding pocket of Grb2-SH2, and is capable of making many of the 
same contacts observed in crystal structures with pTyr-containing peptides.30
3. Conclusion
In summary, our structural and computational data provide unique molecular-level 
explanations for the pTyr mimicry and cell uptake of the bicyclic scaffold BC1. Because 
scaffolds HT1 and BC3 show similar uptake profiles, diverse classes of neutrally charged, 
constrained scaffolds may be more readily designed than previously assumed. Future work 
will seek to diversify these scaffolds, clarify their uptake mechanisms, maximize endosomal 
escape, and apply them in selections and de novo design. Ultimately, these studies will 
reveal general principles for promoting high degrees of structure and cell penetration for 
non-helical, non-cationic peptides.
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Chemical structures of the BC1 scaffold and BODIPY-FL-labeled analogs. R1 is the adduct 
of hydrazine-functionalized BODIPY-FL, and R2 is the adduct of maleimide-functionalized 
BODIPY-FL. Fluorescein-labeled peptides were also prepared and tested to rule out dye-
dependent effects on cell uptake. HT1-Neut and HT1-Neg are head-to-tail cyclic analogs of 
BC1-Neut and BC1-Neg, and Lin-Neut and Lin-Neg are linear analogs of BC1-Neut and 
BC1-Neg. See Supplementary Information for complete structural and synthesis details.
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Analysis of peptide internalization by confocal fluorescence microscopy. Mammalian breast 
epithelial cancer cells (MDA-MB-453) were grown to 95% confluence in a 24-well glass-
bottom plate and incubated with 10 μM fluorescently-labeled peptide in PBS for 1 hour at 
37°C or 4°C.8 Low-temperature conditions were used to demonstrate the extent to which the 
uptake process was energy-dependent. Alternatively, cells were pre-treated with 80 μM 
dynasore (a dynamin inhibitor that prevents clathrin-mediated endocytosis)20 for 30 min at 
37° C prior to incubation with dye-labeled peptides at the same temperature. Cells were 
washed thoroughly in PBS prior to imaging by confocal microscopy. While peptides were 
incubated in PBS, we also verified their stability in buffered human serum as described 
previously (Supplementary Figure S3).12
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Quantification of cell fluorescence. (A) Corrected total cell fluorescence (CTCF) of 
individual cells for each experimental condition tested. Images collected by confocal 
fluorescence microscopy were background-subtracted using the ImageJ software suite to 
compute CTCF values for individual cells. The mean CTCF of 5 representative cells within 
each image is plotted. Error bars denote standard deviation. (B) Quantitation of cellular 
internalization by direct fluorometry.31 MDA-MB-453 cells were seeded in a 96 well plate 
at 105 cells/ml and grown for several hours prior to incubation with the indicated 
Quartararo et al. Page 9













concentrations of peptide for 1 hour at 37° C in PBS. Cells were then washed and lysed in 
1% Triton x-100 prior to fluorometric analysis at 485 nm excitation, 535 nm emission. 
Supplementary Figure S8 shows the same data but with a narrower y-axis.
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Solution structure of BC1. (A) NMR-derived structural model of BC1. 90 NOE-derived 
distance constraints were used in two-stages simulated annealing and energy minimization 
using CNSolve.32 The 30 lowest-energy structures are shown. Carbons are shown in light 
gray, side chain carbons of the binding epitope are shown in dark grey, and side chain 
carbons of the cross-link are shown in purple. (B) The atoms of the backbone and cross-link, 
with all other side chain atoms omitted. Backbone RMSD is 0.33 Å. (C) A representative 
structure of BC1 showing the putative binding epitope (transparent surface). A pTyr-
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mimicking epitope is formed by Gly1 and Tyr3. Pro4 organizes a turn that positions Asn5 
on the same face as Glu1 and Tyr3, consistent with established binding modes for peptide 
ligands of Grb2-SH2.30 (D) A representative solution structure of BC1 was docked into the 
phosphotyrosine-binding site of the Grb2-SH2 domain (PDB ID: 1JYR)33 using Molecular 
Operating Environment (Chemical Computing Group) with the OPLS-AA forcefield. The 
protein is depicted as an electrostatic potential surface. Following energy minimization, 
Glu1 and Tyr3 form similar interactions with the Grb2-SH2 domain as pTyr-containing 
peptides.30 Asn5 is able to access a known specificity pocket. (E) A 100 ns molecular 
dynamics simulation of BC1 in explicit water revealed three distinct water-binding pockets 
formed by backbone carbonyls and amide protons. Surface represents the Van der Waals 
surface of BC1. The table shows approximate residence time, fractional occupancy 
(percentage of the simulation steps in which a water occupied the pocket) and calculated 
δδG of binding for each water. (F) Representative NMR structure of BC1 showing heavy 
atoms (blue spheres) that have protons with cross-relaxation peaks with water protons. For 
these protons, the water cross-peak in the ROESY was opposite in sign to the same cross-
peak in the NOESY, which is characteristic of direct magnetization transfer to water 
(Supplementary Figure S11).28,29
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